{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:10:02Z","timestamp":1788174602858,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Single agents have demonstrated activity in relapsed and refractory (R\/R) peripheral T\u2010cell lymphoma (PTCL). Their benefit relative to combination chemotherapy remains undefined. Patients with histologically confirmed PTCL were enrolled in the Comprehensive Oncology Measures for Peripheral T\u2010cell Lymphoma Treatment (COMPLETE) registry. Eligibility criteria included those with R\/R disease who had received one prior systemic therapy and were given either a single agent or combination chemotherapy as first retreatment. Treatment results for those with R\/R disease who received single agents were compared to those who received combination chemotherapy. The primary endpoint was best response to retreatment. Fifty\u2010seven patients met eligibility criteria. At first retreatment, 46% (26\/57) received combination therapy and 54.5% (31\/57) received single agents. At median follow up of 2 years, a trend was seen towards increased complete response rate for single agents versus combination therapy (41% vs 19%;\n                    <jats:italic>P<\/jats:italic>\n                    = .02). There was also increased median overall survival (38.9 vs 17.1 months;\n                    <jats:italic>P<\/jats:italic>\n                    = .02) and progression\u2010free survival (11.2 vs 6.7 months;\n                    <jats:italic>P<\/jats:italic>\n                    = .02). More patients receiving single agents received hematopoietic stem\u2010cell transplantation (25.8% vs 7.7%,\n                    <jats:italic>P<\/jats:italic>\n                    = .07). Adverse events of grade 3 or 4 occurred more frequently in those receiving combination therapy, although this was not statistically significant. The data confirm the unmet need for better treatment in R\/R PTCL. Despite a small sample, the analysis shows greater response and survival in those treated with single agents as first retreatment in R\/R setting, while maintaining the ability to achieve transplantation. Large, randomized trials are needed to identify the best strategy.\n                  <\/jats:p>","DOI":"10.1002\/ajh.25463","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T08:55:38Z","timestamp":1553158538000},"page":"641-649","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Single agents vs combination chemotherapy in relapsed and refractory peripheral T\u2010cell lymphoma: Results from the comprehensive oncology measures for peripheral T\u2010cell lymphoma treatment (COMPLETE) registry"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-5170","authenticated-orcid":false,"given":"Robert N.","family":"Stuver","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies and and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufer","family":"Khan","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Institution name  Clermont Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Acosta","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals, Inc.  Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[{"name":"University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint\u2010Louis  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Lansigan","sequence":"additional","affiliation":[{"name":"Dartmouth\u2010Hitchcock Medical Center  New Hampshire Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Pinter\u2010Brown","sequence":"additional","affiliation":[{"name":"University of California Irvine  Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine  New Haven Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1566-9308","authenticated-orcid":false,"given":"Salvia","family":"Jain","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center  Boston Massachusetts"},{"name":"Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.07.010"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-516245"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"e_1_2_7_8_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: T\u2010Cell Lymphomas Version 5.2018. 2018. Not proper format."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3883"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2144"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13222"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.573031"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30416"},{"issue":"21","key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1182\/blood.V120.21.4263.4263","article-title":"Biomarker quality assurance (QA) findings from the comprehensive oncology measures for peripheral T\u2010Cell lymphoma treatment (COMPLETE) Registry","volume":"120","author":"Hsi ED","year":"2012","journal-title":"Blood."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_27_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Published November 27 2017."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.645818"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq698"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25463","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T18:43:08Z","timestamp":1694371388000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1002\/ajh.25463"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25463","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735372083.793577565","asserted-by":"object"}]},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"2019-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}